DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Tremelimumab is an investigational drug.
There have been 141 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.
There are fifty-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Tremelimumab
|Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma||Asan Medical Center||Phase 2|
|Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma||Yale University||Early Phase 1|
|Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer||AstraZeneca||Phase 2|
Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tremelimumab||Start Trial||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Start Trial|
|Tremelimumab||Start Trial||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||Start Trial|
|Tremelimumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|